BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM)

Clinical trials for BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM) explained in plain language.

Never miss a new study

Get alerted when new BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM) trials appear

Sign up with your email to follow new studies for BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Scientists track rare genetic heart condition for three years

Knowledge-focused Ongoing

This study aims to understand how a specific genetic heart condition (BAG3 dilated cardiomyopathy) naturally progresses over three years. Researchers will observe 35 participants who have this genetic mutation and reduced heart function, while they continue their usual treatments…

Matched conditions: BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM)

Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused

Last updated Apr 01, 2026 14:41 UTC

BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM)

Get alerted when new BCL-2 ANATHOGENE-3 (BAG3) DILATED CARDIOMYOPATHY (DCM) trials appear

Scientists track rare genetic heart condition for three years